Pharmacyclics' (PCYC) Ibrutinib Has $7.5B Potential; Goldman Upgrades to Buy, PT $170
Tweet Send to a Friend
Goldman Sachs upgraded Pharmacyclics (NASDAQ: PCYC) from Neutral to Buy with a price target of $170.00 (from $111.00). Analyst Navdeep ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
